Nathan Krah is an Oncology physician affiliated with University of Utah. OpenAlex indexes 74 publications with 3,008 citations (h-index 18).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingMedicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
100%Statin53.8%Atorvastatin Calcium100%Part D<11 patientsACE inhibitor46.2%Lisinopril100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2015–2026 per NIH RePORTER. The latest:
- The impact of pyruvate metabolic fate in myofibroblast differentiation in myelofibrosis.
Utah State Higher Education System--University of Utah
FY2026$84,148F32HL177926 - The impact of pyruvate metabolic fate in myofibroblast differentiation in myelofibrosis.
Utah State Higher Education System--University of Utah
FY2025$80,224F32HL177926 - A differentiation-based mechanism limiting pancreatic tumor initiation
University of Utah
FY2019$50,016F30CA192819
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Selective Elimination of TP53 Mutant Cells by Transcript-Activated Chromatin Shredding
bioRxiv (Cold Spring Harbor Laboratory)
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Colman, MD
University of Utah
Mark Rapaport, MD
University of Utah
Dennis Shrieve, MD
University of Utah
Frederick Welt, MD
University of Utah
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”